Pemphigus Foliaceus

Pemphigus Foliaceus

No Results

No Results


Pemphigus foliaceus (PF) is generally a benign variety of pemphigus. It is an autoimmune skin disorder characterized by the loss of intercellular adhesion of keratinocytes in the upper parts of the epidermis (acantholysis), resulting in the formation of superficial blisters. It is typified by clinical involvement of healthy-appearing skin that blisters when rubbed (the Nikolsky sign; commonly but incorrectly spelled Nicholsky), a finding named after Dr Piotr Nikolsky, who first described this sign in 1896. [1] Pemphigus foliaceus is characterized by a chronic course, with little or no involvement of the mucous membranes.

Pierre Louis Alphee Cazenave, founder of the first journal dedicated entirely to dermatology, documented the first description of pemphigus foliaceus in 1844 in this journal. The description was of a 47-year-old woman who consulted him at l’Hopital Saint Louis in Paris for a generalized eruption of several years’ duration. Nikolsky described lateral extension of the preexisting erosion due to lifting up the collarette (and when applying a lateral pressure to the clinically intact skin), whereas Asboe-Hansen described extension of the intact blister due to pressure that is applied to its roof.

Pemphigus foliaceus has the following six subtypes: pemphigus erythematosus (PE), pemphigus herpetiformis (PH), endemic pemphigus foliaceus, endemic pemphigus foliaceus with antigenic reactivity characteristic of paraneoplastic pemphigus (but with no neoplasm), immunoglobulin A (IgA) pemphigus foliaceus, and drug-induced pemphigus foliaceus. See Pemphigus Erythematosus; Pemphigus Herpetiformis; Pemphigus, Paraneoplastic; and Pemphigus, IgA for more information.

Senear and Usher originally described PE in 1926 as an unusual type of pemphigus with features of lupus erythematosus. PE (also known as Senear-Usher syndrome) is best viewed as a localized form of pemphigus foliaceus. Chorzelski et al [2] determined its immunopathology in 1968.

Another pemphigus foliaceus variant with pruritic, flaccid vesicles in an annular pattern has been characterized as IgA pemphigus foliaceus, with antibodies of IgA class providing the basis for diagnosis.

Jablonska and associates [3] coined the term pemphigus herpetiformis for the pemphigus foliaceus variant that often begins as small clusters of pruritic papules and vesicles mimicking dermatitis herpetiformis.

Endemic pemphigus foliaceus, or fogo selvagem (formerly known as Brazilian pemphigus foliaceus because it is evident mainly in the river valleys of rural Brazil), has also been described in Columbia, El Salvador, Paraguay, Peru, and Tunisia. Fogo selvagem (Portuguese for wild fire) displays immunopathologic findings of pemphigus and a distinctive epidemiology suggestive of a disorder triggered by an infectious insect-borne agent (see Fogo Selvagem). [4] A focus of endemic pemphigus foliaceus also exists in El Bagre, Columbia and shares features with Senear-Usher syndrome but occurs in an endemic fashion. [5, 6] It also may have autoantibodies to optic nerve sheath envelope cell junctions, the clinical significance of which is unknown. [7] Heterogeneous antigenic reactivity was observed as in paraneoplastic pemphigus but with no evidence of association with neoplasia. This endemic pemphigus disease in El Bagre had immunologic features similar to pemphigus foliaceus or erythematosus.

Chorzelski et al in 1999 [8] described paraneoplastic pemphigus with cutaneous and serologic features of pemphigus foliaceus in a patient with an underlying lymphoma. The authors are not aware of any similar patients with these highly unusual findings.

Drug-induced pemphigus foliaceus is mostly associated with penicillamine, nifedipine, or captopril, medications with a cysteinelike chemical structure.

A transition from pemphigus vulgaris (PV) to pemphigus foliaceus, or vice versa, is not likely. However, in the experience at the Medical University of Warsaw, PV in the remission period may resemble pemphigus foliaceus. About 7% of patients with pemphigus foliaceus may have the initial features of PH. This figure was 35% in patients with endemic pemphigus foliaceus in Tunisia (see Pemphigus Vulgaris). The pivotal contributions of Jean-Claude Bystryn have been summarized. [9]

Superficial blisters in pemphigus foliaceus are induced by immunoglobulin G (IgG) (mainly IgG4 subclass) autoantibodies directed against a cell adhesion molecule, desmoglein 1 (160 kd), expressed mainly in the granular layer of the epidermis. Desmoglein 1 is also a major autoantigen in cases of PH, suggesting that most cases of both PE and PH are clinical variants of pemphigus foliaceus. The mechanism of acantholysis induction by specific autoantibodies may involve phosphorylation of intracellular proteins associated with desmosomes. Complement activation does not play a pathogenic role in pemphigus foliaceus. A polyclonal mixture in pemphigus foliaceus patients of anti-Dsg1 IgG antibodies enhances pathogenic activity for blister formation, with not only pathogenic antibodies, but also nonpathogenic antibodies, contributing to blister formation. [10]

Antibodies against desmoglein 3 are also present in patients with paraneoplastic pemphigus (PNP), a severe condition associated with various antibodies against different components of the cell adhesion complex. Other target antigens, including the acetylcholine receptor, have also been postulated to be relevant in the pathogenesis of pemphigus foliaceus. [11, 12, 13, 14]

Cholinergic control of epidermal cohesion may be important. [15] The regulation of keratinocyte cell-to-cell and cell-matrix adhesion is an important biological function of cutaneous acetylcholine. Progress in therapy of pemphigus using cholinergic drugs supports this concept.

Precipitating factors include medications and ultraviolet light radiation. It has been suggested that both enhanced autoantibody epidermal binding and preferential neutrophil adhesion to UV-irradiated epidermis contribute to acantholysis development in photo-induced pemphigus foliaceus. Radiation therapy may also flare pemphigus foliaceus in those with it. [16, 17, 18]

Endemic pemphigus foliaceus seems to have an environmental cause. The prevalence of antibodies against desmoglein 1 is high in people residing in endemic areas of Brazil, with disease onset preceded by a sustained antibody response due to an as yet unknown environmental factor.

Genetic factors predispose to the development of pemphigus foliaceus. The HLA-DRB1*01:02 allele and the HLA-DRB1*01-DQA1*01-DQB1*05 haplotype had the strongest linkage among 86 pemphigus foliaceus patients from southeastern Brazil. [19] The role of genetic factors is evident in fogo selvagem in which a strong association exists with some human leukocyte antigen DRB1 (HLA-DRB1) haplotypes, including DRB1*0404, 1402, 1406, and 1401. In France, persons with DRB1*0102 and 0404 are at an increased risk of pemphigus foliaceus.

Pemphigus trigger factors have been meticulously analyzed by Ruocco and Ruocco, [20] who have delineated an exhaustive list and stressed the need to detect environmental provoking or precipitating factors. As a superb memory device to facilitate thorough patient evaluation, Ruocco [21] has cleverly observed that PEMPHIGUS should encourage the physician to consider pesticides (PE), malignancy (M), pharmaceuticals (P), hormones (H), infectious agents (I), gastronomy (G), ultraviolet light (U), and stress (S).

Rarely, a change in pemphigus subtype may occur, accompanied by qualitative and quantitative changes in the anti-Dsg autoantibody profile as detected using antigen-specific enzyme-linked immunosorbent assays (ELISAs). Thus, the antibody profile defines the clinical phenotypes of pemphigus, and that intermolecular “epitope spreading” may be the immunological mechanism underlying a shift between pemphigus foliaceus and PV. [22]

It has been suggested that polymorphisms in the 2q33 and 3q21 chromosomal regions influence susceptibility to pemphigus foliaceus. [23]

Scientific evidence links interactions between thymoma function, thymoma, and pemphigus, often associating loss of self-tolerance and the presence of autoimmunity. [24] The association of pemphigus foliaceus and thymoma is noteworthy.

Endemic pemphigus foliaceus in Tunisia has merited analysis. Unlike in North America and Japan, in Tunisia IgG autoantibodies against Dsg1 are commonly detected in healthy individuals. [25] In a Tunisian study, these IgG autoantibodies against Dsg1 were generally against pre-Dsg1 and/or C-terminal domains of Dsg1 in healthy Tunisians.

Endemic pemphigus foliaceus, or fogo selvagem, seems to be induced by a viral infection transmitted by insects.

In some patients, pemphigus foliaceus may be precipitated by extensive UV exposure or burns and by various drugs (eg, penicillamine, [26, 27] inhibitors of angiotensin convertase, nonsteroid anti-inflammatory agents). [28] Pemphigus foliaceus induced by bucillamine has been described. [29]

A topical ectoparasiticide containing fipronil, amitraz, and S-methoprene has been described as causing pemphigus foliaceus in dogs. [30]

The incidence of pemphigus foliaceus varies depending on the population studied. Pemphigus foliaceus is rare and sporadic worldwide. In contrast to PV, no predominance of pemphigus foliaceus is found in Jews and in people of Mediterranean descent. An increased incidence of pemphigus foliaceus was noted in Tunisian women (6.6 cases per million per year), whereas, in Western Europe, the incidence of pemphigus foliaceus is about 0.5-1 case per million per year. [31]

Endemic pemphigus foliaceus, or fogo selvagem, occurs with a high frequency in central and southwestern Brazil and in Colombia. The Terena reservation in Brazil has a prevalence of 3.4% of the population. In endemic regions of Brazil, as many as 50 cases per million per year are seen. [32] Other foci may be present in the Maghreb; one was described in Morocco.

Pemphigus foliaceus has been described in all races.

In general, the prevalence of pemphigus foliaceus in men and women is about equal; however, in the Sousse region of Tunisia, an overwhelming predominance of women are affected. The peak incidence of endemic pemphigus foliaceus in women aged 25-34 years in the Sousse region of Tunisia is 15.5 cases per million per year. In El Salvador, a similar female and age predisposition may also be evident.

The mean patient age at onset of pemphigus foliaceus is about 50-60 years; however, it may occur at any age, from infancy onward. [33] Fogo selvagem often occurs in children, young adults, and genetically related family members. The mean patient age at onset is about 20-30 years. The peak incidence of endemic pemphigus foliaceus occurs in women aged 25-34 years in the Sousse region of Tunisia. An increased incidence in genetically related family members does not appear to exist.

Pemphigus foliaceus tends to persist for months to years. Pemphigus foliaceus may coexist with thymoma, myasthenia gravis, lupus erythematosus, and other autoimmune bullous diseases.

Nikolski PV. Materiali K.uchenigu o pemphigus foliaceus [doctoral thesis]. Kiev. 1896.

Chorzelski T, Jablonska S, Blaszczyk M. Immunopathological investigations in the Senear-Usher syndrome (coexistence of pemphigus and lupus erythematosus). Br J Dermatol. 1968 Apr. 80(4):211-7. [Medline].

Jablonska S, Chorzelski TP, Beutner EH, Chorzelska J. Herpetiform pemphigus, a variable pattern of pemphigus. Int J Dermatol. 1975 Jun. 14(5):353-9. [Medline].

Aoki V, Rivitti EA, Diaz LA. Update on fogo selvagem, an endemic form of pemphigus foliaceus. J Dermatol. 2015 Jan. 42(1):18-26. [Medline].

Abreu-Velez AM, Hashimoto T, Bollag WB, et al. A unique form of endemic pemphigus in northern Colombia. J Am Acad Dermatol. 2003 Oct. 49(4):599-608. [Medline].

Abreu-Velez AM, Beutner EH, Montoya F, Bollag WB, Hashimoto T. Analyses of autoantigens in a new form of endemic pemphigus foliaceus in Colombia. J Am Acad Dermatol. 2003 Oct. 49(4):609-14. [Medline].

Abreu-Velez AM, Gao W, Howard MS. Patients affected by endemic pemphigus foliaceus in Colombia, South America exhibit autoantibodies to optic nerve sheath envelope cell junctions. Dermatol Pract Concept. 2018 Jan. 8 (1):1-6. [Medline].

Chorzelski TP, Hashimoto T, Amagai M, et al. Paraneoplastic pemphigus with cutaneous and serological features of pemphigus foliaceus. Br J Dermatol. 1999 Aug. 141(2):357-9. [Medline].

Grando SA, Holubar K, Schwartz RA. Jean-Claude Bystryn 1938-2010. An obituary. Exp Dermatol. 2011 Mar. 20(3):293-6. [Medline].

Yoshida K, Ishii K, Shimizu A, Yokouchi M, Amagai M, Shiraishi K, et al. Non-pathogenic pemphigus foliaceus (PF) IgG acts synergistically with a directly pathogenic PF IgG to increase blistering by p38MAPK-dependent desmoglein 1 clustering. J Dermatol Sci. 2016 Dec 12. [Medline].

Ishii K, Amagai M, Komai A, et al. Desmoglein 1 and desmoglein 3 are the target autoantigens in herpetiform pemphigus. Arch Dermatol. 1999 Aug. 135(8):943-7. [Medline].

Kubo A, Amagai M, Hashimoto T, et al. Herpetiform pemphigus showing reactivity with pemphigus vulgaris antigen (desmoglein 3). Br J Dermatol. 1997 Jul. 137(1):109-13. [Medline].

Masmoudi A, Baricault S, Chikrouhou H, et al. [Tunisian pemphigus foliaceus with antidesmoglein 3 antibody]. Ann Dermatol Venereol. 2008 Jan. 135(1):69-70. [Medline].

Wu H, Wang ZH, Yan A, et al. Protection against pemphigus foliaceus by desmoglein 3 in neonates. N Engl J Med. 2000 Jul 6. 343(1):31-5. [Medline].

Grando SA. Cholinergic control of epidermal cohesion. Exp Dermatol. 2006 Apr. 15(4):265-82. [Medline].

Kikuchi K, Inokuma D, Moriuchi R, Koguchi-Yoshioka H, Yasui C, Shimizu S. Exacerbation of Pemphigus Foliaceus After Electron-beam Radiation. Acta Derm Venereol. 2014 Mar 13. [Medline].

Inadomi T. A case of pemphigus foliaceus aggravated in an irradiated area by radiotherapy against breast cancer. Indian J Dermatol. 2015 Jan-Feb. 60(1):93-4. [Medline]. [Full Text].

Liebman TN, Lieberman MR, Burris K. Pemphigus foliaceus exacerbated by radiation, in association with myasthenia gravis. Dermatol Online J. 2016 Mar 16. 22 (3):360-4. [Medline].

Brochado MJ, Nascimento DF, Campos W, Deghaide NH, Donadi EA, Roselino AM. Differential HLA class I and class II associations in pemphigus foliaceus and pemphigus vulgaris patients from a prevalent Southeastern Brazilian region. J Autoimmun. 2016 May 10. [Medline].

Ruocco V, Ruocco E. Pemphigus and environmental factors. Giornale Dermatol Venereol. 2003. 138:299-309.

Ruocco V. Attualita’ sul pemfigo indotto. 2003.

Pigozzi B, Peserico A, Schiesari L, Alaibac M. Pemphigus foliaceus evolving into pemphigus vulgaris: a probable example of ‘intermolecular epitope spreading’ confirmed by enzyme-linked immunosorbent assay study. J Eur Acad Dermatol Venereol. 2008 Feb. 22(2):242-4. [Medline].

Dalla-Costa R, Pincerati MR, Beltrame MH, Malheiros D, Petzl-Erler ML. Polymorphisms In the 2q33 and 3q21 Chromosome Regions Including T Cell Coreceptor and Ligand Genes May Influence Susceptibility to Pemphigus Foliaceus. Hum Immunol. 2010 Apr 27. [Medline].

Shelly S, Agmon-Levin N, Altman A, Shoenfeld Y. Thymoma and autoimmunity. Cell Mol Immunol. 2011 Feb 14. [Medline].

Toumi A, Saleh MA, Yamagami J, Abida O, Kallel M, Masmoudi A, et al. Autoimmune reactivity against precursor form of desmoglein 1 in healthy Tunisians in the area of endemic pemphigus foliaceus. J Dermatol Sci. 2013 Feb 19. [Medline].

Brenner S, Ruocco V. D-penicillamine-induced pemphigus foliaceus with autoantibodies to desmoglein-1. J Am Acad Dermatol. 1998 Jul. 39(1):137-8. [Medline].

Olszewska M, Misiewiz J, Kolakowska-Starzyk H. Penicillamine-induced pemphigus herpetiformis (foliaceus). Dermatol Klin (Wroclaw). 2001. 3 (Suppl 1):101.

Lin R, Ladd DJ Jr, Powell DJ, Way BV. Localized pemphigus foliaceus induced by topical imiquimod treatment. Arch Dermatol. 2004 Jul. 140(7):889-90. [Medline].

Fujita H, Iguchi M, Watanabe R, Asahina A. Pemphigus foliaceus induced by bucillamine. Eur J Dermatol. 2007 Jan-Feb. 17(1):98-9. [Medline].

Bizikova P, Linder KE, Olivry T. Fipronil-amitraz-S-methoprene-triggered pemphigus foliaceus in 21 dogs: clinical, histological and immunological characteristics. Vet Dermatol. 2014 Apr. 25(2):103-e30. [Medline].

Bastuji-Garin S, Souissi R, Blum L, et al. Comparative epidemiology of pemphigus in Tunisia and France: unusual incidence of pemphigus foliaceus in young Tunisian women. J Invest Dermatol. 1995 Feb. 104(2):302-5. [Medline].

Warren SJ, Lin MS, Giudice GJ, et al. The prevalence of antibodies against desmoglein 1 in endemic pemphigus foliaceus in Brazil. Cooperative Group on Fogo Selvagem Research. N Engl J Med. 2000 Jul 6. 343(1):23-30. [Medline].

Fariba G, Ayatollahi A, Hejazi S. Pemphigus foliaceus. Indian Pediatr. 2012 Mar 8. 49(3):240-1. [Medline].

Metry DW, Hebert AA, Jordon RE. Nonendemic pemphigus foliaceus in children. J Am Acad Dermatol. 2002 Mar. 46(3):419-22. [Medline].

Daoud YJ, Foster CS, Ahmed R. Eyelid skin involvement in pemphigus foliaceus. Ocul Immunol Inflamm. 2005 Sep-Oct. 13(5):389-94. [Medline].

Uzun S, Durdu M. The specificity and sensitivity of Nikolskiy sign in the diagnosis of pemphigus. J Am Acad Dermatol. 2006 Mar. 54(3):411-5. [Medline].

Grekin SJ, Fox MC, Gudjonsson JE, Fullen DR. Psoriasiform pemphigus foliaceus: a report of two cases. J Cutan Pathol. 2012 Jan 10. [Medline].

Gee SN, Velez NF, Sepehr A, Burgin S. Two distinct viral infections complicating pemphigus foliaceus. Dermatol Online J. 2012 Jan 15. 18(1):3. [Medline].

Kraigher O, Wohl Y, Gat A, Brenner S. A mixed immunoblistering disorder exhibiting features of bullous pemphigoid and pemphigus foliaceus associated with Spirulina algae intake. Int J Dermatol. 2008 Jan. 47(1):61-3. [Medline].

Jarzabek-Chorzelska M, Jablonska S, Kolacinska-Strasz Z, Sulej I. Immunopathological diagnosis of pemphigus foliaceus. Dermatology. 2002. 205(4):413-5; author reply 415-6; discussion 416. [Medline].

Kumaresan M, Rai R, Sandhya V. Immunofluorescence of the outer root sheath: an aid to diagnosis in pemphigus. Clin Exp Dermatol. 2010 Dec 24. [Medline].

Harman KE, Gratian MJ, Seed PT, Bhogal BS, Challacombe SJ, Black MM. Diagnosis of pemphigus by ELISA: a critical evaluation of two ELISAs for the detection of antibodies to the major pemphigus antigens, desmoglein 1 and 3. Clin Exp Dermatol. 2000 May. 25(3):236-40. [Medline].

Martel P, Gilbert D, Labeille B, Kanitakis J, Joly P. A case of paraneoplastic pemphigus with antidesmoglein 1 antibodies as determined by immunoblotting. Br J Dermatol. 2000 Apr. 142(4):812-3. [Medline].

Narbutt J, Sysa-Jedrzejowska A, Torzecka JD. The usefulness of enzyme-linked immunosorbent assay for serodiagnosis of pemphigus vulgaris and pemphigus foliaceus at various stages of diseaseactivity. Przegl Dermatol. 2002. 89:447-452.

Nagao K, Tanikawa A, Yamamoto N, Amagai M. Decline of anti-desmoglein 1 IgG ELISA scores by withdrawal of D-penicillamine in drug-induced pemphigus foliaceus. Clin Exp Dermatol. 2005 Jan. 30(1):43-5. [Medline].

Martin LK, Werth V, Villanueva E, Segall J, Murrell DF. Interventions for pemphigus vulgaris and pemphigus foliaceus. Cochrane Database Syst Rev. 2009 Jan 21. CD006263. [Medline].

Grando SA. New approaches to the treatment of pemphigus. J Investig Dermatol Symp Proc. 2004 Jan. 9(1):84-91. [Medline].

Murrell DF, Dick S, Ahmed AR, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol. 2008 Jun. 58(6):1043-6. [Medline].

Dumas V, Roujeau JC, Wolkenstein P, Revuz J, Cosnes A. The treatment of mild pemphigus vulgaris and pemphigus foliaceus with a topical corticosteroid. Br J Dermatol. 1999 Jun. 140(6):1127-9. [Medline].

Gupta R. Prolonged remission of pemphigus induced by dexamethasone-cyclophosphamide pulse therapy. Indian J Dermatol Venereol Leprol. 2007 Mar-Apr. 73(2):121-2. [Medline].

Katz KH, Marks JG Jr, Helm KF. Pemphigus foliaceus successfully treated with mycophenolate mofetil as a steroid-sparing agent. J Am Acad Dermatol. 2000 Mar. 42(3):514-5. [Medline].

Chaffins ML, Collison D, Fivenson DP. Treatment of pemphigus and linear IgA dermatosis with nicotinamide and tetracycline: a review of 13 cases. J Am Acad Dermatol. 1993 Jun. 28(6):998-1000. [Medline].

Herr AL, Hatami A, Kokta V, Dalle JH, Champagne MA, Duval M. Successful anti-CD20 antibody treatment of pemphigus foliaceus after unrelated cord blood transplantation. Bone Marrow Transplant. 2005 Feb. 35(4):427-8. [Medline].

Amagai M, Ikeda S, Shimizu H, et al. A randomized double-blind trial of intravenous immunoglobulin for pemphigus. J Am Acad Dermatol. 2009 Apr. 60(4):595-603. [Medline].

Toth GG, Jonkman MF. Successful treatment of recalcitrant penicillamine-induced pemphigus foliaceus by low-dose intravenous immunoglobulins. Br J Dermatol. 1999 Sep. 141(3):583-5. [Medline].

Martin LK, Werth VP, Villaneuva EV, Murrell DF. A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus. J Am Acad Dermatol. 2011 Feb 24. [Medline].

Daniel BS, Murrell DF. The actual management of pemphigus. G Ital Dermatol Venereol. 2010 Oct. 145(5):689-702. [Medline].

Marzano AV, Fanoni D, Venegoni L, Berti E, Caputo R. Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab). Dermatology. 2007. 214(4):310-8. [Medline].

Alter M, Wittmann M, Volker B, Kapp A, Werfel T, Gutzmer R. [Successful treatment of pemphigus foliaceus with rituximab : Report of 3 cases.]. Hautarzt. 2009 Jan 18. [Medline].

de Sena Nogueira Maehara L, Huizinga J, Jonkman MF. Rituximab therapy in pemphigus foliaceus: report of 12 cases and review of recent literature. Br J Dermatol. 2014 Dec 13. [Medline].

Wei KC, Wang YH, Wang WH, Chen W. Fatal infection of Pneumocystis jiroveci pneumonia in a pemphigus patient treated with rituximab. J Eur Acad Dermatol Venereol. 2017 Jan 27. [Medline].

Lolis M, Toosi S, Czernik A, Bystryn JC. Effect of intravenous immunoglobulin with or without cytotoxic drugs on pemphigus intercellular antibodies. J Am Acad Dermatol. 2011 Mar. 64(3):484-9. [Medline].

Iskandarli M, Gerceker Turk B, Ertam I, Yaman B, Ozturk G. Successful treatment of Wilson disease-associated IgA pemphigus with IVIG. J Eur Acad Dermatol Venereol. 2015 Mar 12. [Medline].

Doukaki S, Platamone A, Alaimo R, Bongiorno MR. Mycophenolate mofetil and enteric-coated mycophenolate sodium in the treatment of pemphigus vulgaris and pemphigus foliaceus. J Dermatolog Treat. 2014 Feb 13. [Medline].

Tavakolpour S. Pemphigus trigger factors: special focus on pemphigus vulgaris and pemphigus foliaceus. Arch Dermatol Res. 2018 Mar. 310 (2):95-106. [Medline].

Robert A Schwartz, MD, MPH Professor and Head of Dermatology, Professor of Pathology, Pediatrics, Medicine, and Preventive Medicine and Community Health, Rutgers New Jersey Medical School; Visiting Professor, Rutgers University School of Public Affairs and Administration

Robert A Schwartz, MD, MPH is a member of the following medical societies: Alpha Omega Alpha, New York Academy of Medicine, American Academy of Dermatology, American College of Physicians, Sigma Xi

Disclosure: Nothing to disclose.

Slawomir Majewski, MD Professor and Director, Department of Dermatology and Venereology, Warsaw School of Medicine, Poland

Disclosure: Nothing to disclose.

Sebastian S Majewski 

Disclosure: Nothing to disclose.

Michael J Wells, MD, FAAD Dermatologic/Mohs Surgeon, The Surgery Center at Plano Dermatology

Michael J Wells, MD, FAAD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, Texas Medical Association

Disclosure: Nothing to disclose.

Julia R Nunley, MD Professor, Program Director, Dermatology Residency, Department of Dermatology, Virginia Commonwealth University Medical Center

Julia R Nunley, MD is a member of the following medical societies: American Academy of Dermatology, American College of Physicians, American Society of Nephrology, International Society of Nephrology, Medical Dermatology Society, Medical Society of Virginia, National Kidney Foundation, Phi Beta Kappa, Women’s Dermatologic Society

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: American Board of Dermatology<br/>Co-Editor for the text Dermatological Manifestations of Kidney Disease .

Dirk M Elston, MD Professor and Chairman, Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina College of Medicine

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Robin Travers, MD Assistant Professor of Medicine (Dermatology), Dartmouth University School of Medicine; Staff Dermatologist, New England Baptist Hospital; Private Practice, SkinCare Physicians

Robin Travers, MD is a member of the following medical societies: American Academy of Dermatology, American Medical Informatics Association, Massachusetts Medical Society, Women’s Dermatologic Society, Medical Dermatology Society

Disclosure: Nothing to disclose.

Pemphigus Foliaceus

Research & References of Pemphigus Foliaceus|A&C Accounting And Tax Services